Zoetis Inc. Class A (ZTS)
NYSE: ZTSHealthcareDrug Manufacturers - Specialty & GenericUSD
At close: Oct 7, 4:02 PM ET · Delayed 15 min
After hours: 71.55 0.00%
ZTS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $29.57B
- P/E (TTM)
- 11.79
- Forward P/E
- 10.93
- EPS (TTM)
- $6.07
- Dividend yield
- 2.88% ($2.06)
- Ex-dividend date
- Jul 20, 2026
- 52-week range
- 68.77 – 148.30
- Day range
- 71.12 – 72.09
- Volume / Avg
- 4.13M / 5.46M
- Beta
- —
- Shares outstanding
- 413.22M
- Next earnings
- Nov 5, 2026
52-week range
ZTS stock today
On Oct 7, ZTS ended the session at $71.55, adding $0.22 (0.31%), versus the S&P 500's 0.22% decline. Shares are 51.8% below their 52-week high of $148.30, set on Oct 22, 2025 and 4.0% above the 52-week low of $68.77, near the bottom of the past year's range. ZTS is down 43.1% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 49.8%.
At 11.8x trailing earnings, Zoetis trades below the peer-group median of 24.5x. Its forward P/E of 10.9x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Zoetis's next earnings report is expected on Nov 5, 2026. Zoetis pays an annual dividend of $2.06 per share, a 2.88% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Zoetis
Company profileZoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Ms. Kristin C. Peck
- Headquarters
- Parsippany, NJ
- Employees
- 14,500
- IPO year
- 2013
- Website
- zoetis.com
Financial highlights
Full financialsIn fiscal 2025, Zoetis generated $9.47 billion in revenue, up 2.3% from fiscal 2024, its 10th consecutive year of revenue growth. Net income was $2.67 billion (+7.5% year over year), for a net margin of 28.2% versus a median of 26.2% in the prior 5 years. Gross margin was 71.8% (up from 70.6%).
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $9.47B | $9.26B | $8.54B | $8.08B | $7.78B |
| Growth | +2.28% | +8.33% | +5.74% | +3.91% | +16.49% |
| Net income | $2.67B | $2.49B | $2.34B | $2.11B | $2.04B |
| EPS (diluted) | $6.02 | $5.47 | $5.07 | $4.49 | $4.27 |
Analyst forecast
ForecastConsensus (17 analysts)
buy
Avg. price target
$96.00+34.17%
- Strong buy 4
- Buy 4
- Hold 9
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $1.52
- Last reported (Q2 2026)
- Aug 6, 2026
- EPS actual vs est.
- $1.65 vs —
Dividends
Dividend history- Annual dividend
- $2.06
- Dividend yield
- 2.88%
- Last payment
- $0.53
- Ex-dividend date
- Jul 20, 2026
Zoetis peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| UTHRUnited Therapeutics Corporation | 545.00 | +0.62% | $23.38B | vs ZTS |
| VTRSViatris Inc. | 17.49 | -0.29% | $20.09B | vs ZTS |
| HLNHaleon plc ADR | 9.02 | +1.69% | $39.67B | vs ZTS |
| NBIXNeurocrine Biosciences Inc. | 143.47 | -1.40% | $14.58B | vs ZTS |
| TEVATeva Pharmaceutical Industries Limited | 39.18 | +0.13% | $45.70B | vs ZTS |
| ELANElanco Animal Health Incorporated | 22.36 | -0.53% | $11.17B | vs ZTS |
| RDYDr. Reddy's Laboratories Ltd | 12.27 | -1.76% | $10.22B | vs ZTS |
| ALKSAlkermes plc | 41.45 | -0.49% | $6.95B | vs ZTS |
Indexes, lists and sector
Index membership
Appears in lists
Zoetis stock FAQ
What is Zoetis's stock price today?
ZTS last traded at $71.55 as of Oct 7, 4:02 PM EDT, up 0.31% on the day. Prices are delayed at least 15 minutes.
Does Zoetis pay a dividend?
Yes. Zoetis pays $2.06 per share annually, a 2.88% yield. The most recent dividend of $0.53 had an ex-dividend date of Jul 20, 2026.
When is Zoetis's next earnings date?
Zoetis is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $1.52.
What is ZTS's P/E ratio?
ZTS trades at a trailing P/E ratio of 11.79 and a forward P/E of 10.93, compared with a median of 24.5 for its closest peers.
Is Zoetis in the S&P 500?
Yes. Zoetis (ZTS) is a constituent of the S&P 500 index.
Who is Zoetis's CEO?
Ms. Kristin C. Peck is the chief executive officer of Zoetis Inc. Class A, which has about 14,500 employees.
What is the ZTS 52-week high?
The 52-week high for ZTS is $148.30 and the 52-week low is $68.77. The stock is currently 51.8% below its high.